Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Azacitidine/decitabine/venetoclax

Lack of efficacy and off-label use: 11 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Serpenti F, et al. Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse. Leukemia and Lymphoma 63: 2743-2746, No. 11, Jan 2022. Available from: URL: https://www.tandfonline.com/loi/ilal20 Serpenti F, et al. Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse. Leukemia and Lymphoma 63: 2743-2746, No. 11, Jan 2022. Available from: URL: https://​www.​tandfonline.​com/​loi/​ilal20
Metadaten
Titel
Azacitidine/decitabine/venetoclax
Lack of efficacy and off-label use: 11 case reports
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-40912-3

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs